These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 32781784)
21. Anemonin Attenuates RANKL-Induced Osteoclastogenesis and Ameliorates LPS-Induced Inflammatory Bone Loss in Mice Hou H; Peng Q; Wang S; Zhang Y; Cao J; Deng Y; Wang Y; Sun WC; Wang HB Front Pharmacol; 2019; 10():1696. PubMed ID: 32116686 [TBL] [Abstract][Full Text] [Related]
22. Saikosaponin a inhibits RANKL-induced osteoclastogenesis by suppressing NF-κB and MAPK pathways. Zhou C; Liu W; He W; Wang H; Chen Q; Song H Int Immunopharmacol; 2015 Mar; 25(1):49-54. PubMed ID: 25617149 [TBL] [Abstract][Full Text] [Related]
23. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal. Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731 [TBL] [Abstract][Full Text] [Related]
24. Cyperus Rotundus L. extract suppresses RANKL-induced osteoclastogenesis through NFATc1/c-fos downregulation and prevent bone loss in OVX-induced osteoporosis rat. Kum CJ; Kim EY; Kim JH; Lee B; Min JH; Heo J; Kim JH; Yeom M; Sohn Y; Jung HS J Ethnopharmacol; 2017 Jun; 205():186-194. PubMed ID: 28315458 [TBL] [Abstract][Full Text] [Related]
25. Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo. Sakai E; Aoki Y; Yoshimatsu M; Nishishita K; Iwatake M; Fukuma Y; Okamoto K; Tanaka T; Tsukuba T Phytomedicine; 2016 Jul; 23(8):828-37. PubMed ID: 27288918 [TBL] [Abstract][Full Text] [Related]
26. Chaenomelis fructus inhibits osteoclast differentiation by suppressing NFATc1 expression and prevents ovariectomy-induced osteoporosis. Kim M; Kim HS; Kim JH; Kim EY; Lee B; Lee SY; Jun JY; Kim MB; Sohn Y; Jung HS BMC Complement Med Ther; 2020 Feb; 20(1):35. PubMed ID: 32024503 [TBL] [Abstract][Full Text] [Related]
27. Ameliorative effect of Choi YJ; Fan M; Tang Y; Moon S; Lee SH; Lee B; Bae SM; Lee SM; Kim EK Nutr Res Pract; 2022 Aug; 16(4):419-434. PubMed ID: 35919286 [TBL] [Abstract][Full Text] [Related]
28. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972 [TBL] [Abstract][Full Text] [Related]
29. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice. Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189 [TBL] [Abstract][Full Text] [Related]
30. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways. Li CH; Xu LL; Jian LL; Yu RH; Zhao JX; Sun L; Du GH; Liu XY Int Immunopharmacol; 2018 May; 58():136-144. PubMed ID: 29587202 [TBL] [Abstract][Full Text] [Related]
31. The induction of activating transcription factor 3 (ATF3) contributes to anti-cancer activity of Abeliophyllum distichum Nakai in human colorectal cancer cells. Park GH; Park JH; Eo HJ; Song HM; Woo SH; Kim MK; Lee JW; Lee MH; Lee JR; Koo JS; Jeong JB BMC Complement Altern Med; 2014 Dec; 14():487. PubMed ID: 25494848 [TBL] [Abstract][Full Text] [Related]
32. Oxidation derivative of (-)-epigallocatechin-3-gallate (EGCG) inhibits RANKL-induced osteoclastogenesis by suppressing RANK signaling pathways in RAW 264.7 cells. Xu H; Liu T; Li J; Xu J; Chen F; Hu L; Zhang B; Zi C; Wang X; Sheng J Biomed Pharmacother; 2019 Oct; 118():109237. PubMed ID: 31376653 [TBL] [Abstract][Full Text] [Related]
33. Sappanone A inhibits RANKL-induced osteoclastogenesis in BMMs and prevents inflammation-mediated bone loss. Choo YY; Tran PT; Min BS; Kim O; Nguyen HD; Kwon SH; Lee JH Int Immunopharmacol; 2017 Nov; 52():230-237. PubMed ID: 28946117 [TBL] [Abstract][Full Text] [Related]
34. Carnosic acid attenuates RANKL-induced oxidative stress and osteoclastogenesis via induction of Nrf2 and suppression of NF-κB and MAPK signalling. Thummuri D; Naidu VGM; Chaudhari P J Mol Med (Berl); 2017 Oct; 95(10):1065-1076. PubMed ID: 28674855 [TBL] [Abstract][Full Text] [Related]
35. The complete chloroplast genome of a new candidate cultivar, Sang Jae, of Min J; Kim Y; Xi H; Jang T; Kim G; Park J; Park JH Mitochondrial DNA B Resour; 2019 Oct; 4(2):3716-3718. PubMed ID: 33366157 [TBL] [Abstract][Full Text] [Related]
36. Dynein light chain LC8 inhibits osteoclast differentiation and prevents bone loss in mice. Kim H; Hyeon S; Kim H; Yang Y; Huh JY; Park DR; Lee H; Seo DH; Kim HS; Lee SY; Jeong W J Immunol; 2013 Feb; 190(3):1312-8. PubMed ID: 23293355 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185 [TBL] [Abstract][Full Text] [Related]
38. Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation. Tsuji-Naito K Bioorg Med Chem; 2008 Oct; 16(20):9176-83. PubMed ID: 18823786 [TBL] [Abstract][Full Text] [Related]
39. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways. Song J; Jing Z; Hu W; Yu J; Cui X Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958 [TBL] [Abstract][Full Text] [Related]
40. Orostachys japonicus Suppresses Osteoclast Differentiation by Inhibiting NFATc1 Expression. Shim KS; Ha H; Kim T; Lee CJ; Ma JY Am J Chin Med; 2015; 43(5):1013-30. PubMed ID: 26205967 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]